Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Today Analyst firm Credit Suisse gave an Outperform rating on the stock as well as an $15 price target. If AFMD was to rally to this level, it would be a gain of more than 93%.
NO ONE IS TALKING ABOUT THIS STOCK +93% upside potential #shorts
